Evolus (EOLS) Stock Price, News & Analysis

Company Overview

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Key Stats

• Today's Range: $10.73 to $11.16
• 50-Day Range: $10.87 to $17.45
• 52-Week Range: $9.70 to $17.82
• Volume: 979,904 shs
• Average Volume: 590,536 shs
• Market Capitalization: $689.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Buy

Evolus Stock Analysis - MarketRank™

Evolus scored higher than 76% of companies evaluated by MarketBeat, and ranked 244th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Evolus has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evolus are expected to grow in the coming year, from ($0.63) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evolus is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evolus is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.23% of the outstanding shares of Evolus have been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Evolus has recently decreased by 1.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evolus does not currently pay a dividend.

Dividend Growth

Evolus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.27

Percentage of Shares Shorted

8.23% of the outstanding shares of Evolus have been sold short.

Short Interest Ratio / Days to Cover

Evolus has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Evolus has recently decreased by 1.51%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Evolus has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Evolus this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evolus insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Evolus is held by insiders.

Percentage Held by Institutions

90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EOLS Stock Analysis - Frequently Asked Questions

How have EOLS shares performed this year?

Evolus' stock was trading at $10.53 on January 1st, 2024. Since then, EOLS stock has increased by 3.4% and is now trading at $10.89.
View the best growth stocks for 2024 here.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) issued its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The company had revenue of $20.58 million for the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 847.60% and a negative net margin of 22.33%.
Read the conference call transcript.

When did Evolus IPO?

Evolus (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Evolus' top institutional shareholders include Caligan Partners LP (3.46%), Stonepine Capital Management LLC (2.16%), State Street Corp (2.02%) and Geode Capital Management LLC (1.91%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Lauren P Silvernail, Tomoko Yamagishi-Dressler, David N Gill, Robert Hayman and Crystal Muilenburg.
View institutional ownership trends.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 3/23/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EOLS
• CUSIP: N/A
• CIK: 1570562
• Web: www.evolus.com
• Phone: (949) 284-4555
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.00
• High Stock Price Target: $27.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +111.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-61,690,000.00
• Net Margins: -22.33%
• Pretax Margin: -22.20%
• Return on Equity: -847.60%
• Return on Assets: -22.15%

Debt

• Debt-to-Equity Ratio: 20.58
• Current Ratio: 2.47
• Quick Ratio: 2.23

Sales & Book Value

• Annual Sales: $248.33 million
• Price / Sales: 2.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.36) per share
• Price / Book: -30.25

Miscellaneous

• Outstanding Shares: 63,321,000
• Free Float: 59,458,000
• Market Cap: $689.57 million
• Optionable: Optionable
• Beta: 1.27